Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRX103 + cyclophosphamide
- Development stage
- Phase 2
- Lead developer
- Tr1X
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TRX103 + cyclophosphamide is an experimental combination therapy involving TRX103, an investigational agent, and cyclophosphamide, a well-established alkylating antineoplastic and immunosuppressive small molecule. TRX103 is being studied for immune modulation in Crohn's disease; its mechanism likely involves immune system regulation, though its precise target is not specified in available data. Cyclophosphamide acts as a DNA-alkylating agent, forming DNA crosslinks to inhibit cancer cell proliferation and possesses immunosuppressive properties. The combination aims to leverage immune modulation for therapeutic effect in inflammatory diseases such as Crohn's disease, expanding upon cyclophosphamide’s historical antitumor and immunosuppressive utility[5].
02
Targets
DNA
Beyond the preview
Go deeper on TRX103 + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRX103 + cyclophosphamide.